Obstetrics & Gynaecology Forum Volume 29 | Issue 3 | 2019

Pabal ® is indicated for the PREVENTION of UTERINE atony following delivery of the infant by CAESAREAN SECTION under epidural or spinal anaesthesia. 1 References: 1. Pabal ® Registered Package Insert, dated 24 October 2017. 2. Hunter DJS, et al. Effect of carbetocin, a long-acting oxytocin analog on the postpartum uterus. CLIN PHARMACOL THER 1992;52(1):60–67. 3. Dansereau J, et al. Double-blind comparison of carbetocin versus oxytocin in prevention of uterine atony after cesarean section. Am J Obstet Gynecol 1999;180:670–676. 4. Moertl MG, et al. Haemodynamic effects of carbetocin and oxytocin given as intravenous bolus on women undergoing caesarean delivery: a randomised trial. BJOG 2011;118:1349–1356 NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE OF REGISTRATION: FERRING (Pty.) Ltd, Route 21 Corporate Park, 6 Regency Drive, Irene Ext 30. Pretoria, South Africa. Tel: +27 12 345 6358 Fax: +27 12 345 1156 . www.ferring.co.za . PABAL, FERRING, and the FERRING logo are registered trademarks of Ferring B.V. For full prescribing information please refer to the package insert approved by the medicines regulatory authority. 2019/002 Date of preparation: February 2019. S3 PABAL ® (solution for injection). Contains carbetocin (anhydrous acetic acid free): 100 micrograms/ml. Reg. No: A42/19/0383 Pabal ® is now available in a vial... Refrigeration not required Pabal ® is a long-acting analogue of human oxytocin with a half life of 40 minutes 1 Pabal ® stimulates uterine contractility within 2 minutes 2 and provides protection against uterine atony for up to 48 hours 3 Pabal ® and oxytocin have comparable cardiovascular effects, where patients return to baseline haemodynamic levels after ~ 500 seconds 4 Pabal ® is administered as a single intravenous dose of 100 μg (1 ml) 1 One step ahead of uterine atony NOW AVAILABLE in a ROOM TEMPERATURE STABLE FORMULATION! One step ahead of ute One step ahead of uterine atony